Characteristics and Results of Patients Treated by Therapeutic Intensification

Launched by UNIVERSITY HOSPITAL, STRASBOURG, FRANCE · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at patients who have undergone a specific treatment for blood cancers called therapeutic intensification, followed by a procedure known as an autograft, where a patient’s own stem cells are used to help their body recover. The researchers want to learn more about the experiences and outcomes of these patients, especially those who needed extra care in the intensive care unit (ICU) shortly after their treatment. The study will include patients who were treated at the Hautepierre hospital in Strasbourg between 2013 and 2022.

To be eligible for this trial, participants need to be adults aged 18 or older who were admitted to the ICU within 30 days after their treatment. It's important to note that if someone has previously said they do not want their medical information used for research, they won't be included in the study. Those who participate will help researchers understand better how these treatments work and identify factors that might predict how well patients will do after their treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patient (≥18 years old)
• • Gender indifferent
• • Admitted to the Intensive Care Unit within thirty days following therapeutic intensification and autograft of peripheral stem cells for the treatment of a hematologic malignancy between 01/01/2013 and 12/31/2022
• Exclusion Criteria:
• • - Subject having expressed his opposition to the reuse of his data for scientific research purposes